NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant. Specifically, it claims that: - Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate statistically significant improvement [3]. - A prespecified analysis was added to the Phase Two statistical analysis plan focusing on patients with moderate to severe MDD [3]. - The Phase Two Trials lacked adequate data, particularly concerning patient population size and gender ratio, which hindered accurate predictions for the KOASTAL-1 study results [3]. Next Steps - Investors who suffered losses in Neumora Therapeutics, Inc. during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].